Skip to main content
SpringerLink
Log in

Verlafaxine XR: effective in long term management of generalised anxiety disorder

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Barman Balfour JA, Jarvis B. Venlafaxine extended-release. A review of its clinical potential in the management of generalised anxiety disorder. CNS Drugs 2000 Dec; 14(6): 483–123

    Article  Google Scholar 

  2. Fulton B, Brogden RN. Buspirone: an updated review of its clinical pharmacology and therapeutic applications. CNS Drugs 1997; 7: 68–88

    Article  CAS  Google Scholar 

  3. Muth EA, Haskins JT, Moyer JA, et al. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986; 35: 4493–7

    Article  PubMed  CAS  Google Scholar 

  4. Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000 Jun; 157(6): 968–74

    Article  PubMed  CAS  Google Scholar 

  5. Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalised anxiety disorder: a 6-month randomized controlled trial. JAMA 2000 Jun 21; 283(23): 3082–8

    Article  PubMed  CAS  Google Scholar 

  6. Hackett D, Parks V, Salinas E. A 6-month evaluation of 3 dose levels of venlafaxine extended-release in non-depressed outpatients with generalized anxiety disorder. Poster presented at the ADAA; 26 Mar 1999; San Diego

    Google Scholar 

  7. Wyeth Ayerst Inc. Data on file, 2000

  8. Hackett D, Haudiquet V, Salinas E. Controlling for the placebo response rate: a methodological approach to data from double-blind studies with high placebo response [poster presented at BAP, Harrogate]. British Association of Pharmacology 1999 Jul

  9. Niklson IA, Reimitz P-E, Sennef C. Factors that influence the outcome of placebo-controlled antidepressant clinical trials. Psychopharmacol Bull 1997; 33(1): 41–51

    PubMed  CAS  Google Scholar 

  10. Wyeth Laboratories Inc. Effexor XR (venlafaxine hydrochloride) extended release capsules. Prescribing information [on line]. Wyeth Laboratories Inc. Revised 22 Mar, 1999. Available from: URL: http://www.effexorxr.com/pi/pi.htm [Accessed 3 May, 2000]

  11. Troy SM, Turner MB, Unruh M, et al. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and ethanol. J Clin Pharmacol 1997 Nov; 37: 1073–81

    PubMed  CAS  Google Scholar 

  12. Troy SM, Lucki I, Peirgies AA, et al. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. J Clin Pharmacol 1995 Apr; 35: 410–9

    PubMed  CAS  Google Scholar 

  13. O’Hanlon JF, Robbe HWJ, Vermeeren A, et al. Venlafaxine’s effects on healthy volunteers’ driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens. J Clin Psychopharmacol 1998 Jun; 18: 212–21

    Article  PubMed  Google Scholar 

  14. Luthringer R, Toussaint M, Schaltenbrand N, et al. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression. Psychopharmacol Bull 1996; 32(4): 637–46

    PubMed  CAS  Google Scholar 

  15. Hemmeter U, Brüderlin U, Hatzinger M, et al. Effects of venlafaxine on sleep EEG during antidepressant treatment [abstract]. Pharmacopsychiatry 1999 Sep; 32: 185

    Google Scholar 

  16. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998 Oct; 59: 122–8

    Article  Google Scholar 

  17. Heisler MA, Guidry JR, Arnecke B. Serotonin syndrome induced by administration of venlafaxine and phenelzine [letter]. Ann Pharmacother 1996; 30: 84

    PubMed  CAS  Google Scholar 

  18. Phillips SD, Ringo P. Phenelzine and venlafaxine interaction [letter]. Am J Psychiatry 1995; 152: 1400–1

    PubMed  CAS  Google Scholar 

  19. Klysner R, Larsen JK, Sorensen P, et al. Toxic interaction of venlafaxine and isocarboxazide [letter]. Lancet 1995; 346: 1298–9

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Verlafaxine XR: effective in long term management of generalised anxiety disorder. Drugs Ther. Perspect 17, 1–4 (2001). https://doi.org/10.2165/00042310-200117140-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200117140-00001

Keywords

Search

Navigation